Welcome to Markets Desk, your midday read on the stories moving money and markets.
Eli Lilly is making a bold play in non-opioid pain management, spending billions to challenge Vertex Pharmaceuticals, which has a meaningful head start in that space. The move signals Lilly isn't content to rest on its GLP-one dominance — it's diversifying aggressively, and both stocks are worth watching closely as the competitive picture sharpens.
Shifting to tech, Jensen Huang is making the case that software companies are the next wave of AI beneficiaries, and the market is starting to price that in. Veeva Systems and Adobe have both seen significant share price declines recently, which Huang's comments suggest may be creating an entry point for investors willing to bet on the AI-driven software upgrade cycle playing out over the next several years.
And over at Disney, the studio is leaning on a familiar franchise to do some heavy lifting. Toy Story five is being positioned as a potential catalyst for a stock that is down more than forty percent over the past five years. Whether a beloved sequel can move the needle on a company wrestling with streaming economics and theme park pressures remains a very open question.
That's the tape. Markets Desk, signing off the floor.
